DK3694863T3 - Krystallinsk form af frit basehydrat af lorlatinib - Google Patents
Krystallinsk form af frit basehydrat af lorlatinib Download PDFInfo
- Publication number
- DK3694863T3 DK3694863T3 DK18795807.9T DK18795807T DK3694863T3 DK 3694863 T3 DK3694863 T3 DK 3694863T3 DK 18795807 T DK18795807 T DK 18795807T DK 3694863 T3 DK3694863 T3 DK 3694863T3
- Authority
- DK
- Denmark
- Prior art keywords
- lorlatinib
- free base
- crystalline form
- base hydrate
- hydrate
- Prior art date
Links
- 239000012458 free base Substances 0.000 title 1
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title 1
- 229950001290 lorlatinib Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US201862727734P | 2018-09-06 | 2018-09-06 | |
| PCT/IB2018/057735 WO2019073347A1 (en) | 2017-10-10 | 2018-10-04 | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3694863T3 true DK3694863T3 (da) | 2023-07-03 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18795807.9T DK3694863T3 (da) | 2017-10-10 | 2018-10-04 | Krystallinsk form af frit basehydrat af lorlatinib |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (enExample) |
| EP (1) | EP3694863B1 (enExample) |
| JP (1) | JP7153069B2 (enExample) |
| KR (1) | KR102424621B1 (enExample) |
| CN (1) | CN111201235B (enExample) |
| AU (1) | AU2018349259B2 (enExample) |
| CA (1) | CA3077508C (enExample) |
| CY (1) | CY1126141T1 (enExample) |
| DK (1) | DK3694863T3 (enExample) |
| ES (1) | ES2952985T3 (enExample) |
| FI (1) | FI3694863T3 (enExample) |
| HU (1) | HUE062926T2 (enExample) |
| MX (1) | MX2020003373A (enExample) |
| PL (1) | PL3694863T3 (enExample) |
| PT (1) | PT3694863T (enExample) |
| RU (1) | RU2022109286A (enExample) |
| SG (1) | SG11202002445SA (enExample) |
| SI (1) | SI3694863T1 (enExample) |
| TW (1) | TWI775960B (enExample) |
| WO (1) | WO2019073347A1 (enExample) |
| ZA (1) | ZA202001661B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2842302T3 (es) | 2015-07-31 | 2021-07-13 | Pfizer | Forma cristalina de base libre de lorlatinib |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| US20210163498A1 (en) * | 2018-04-23 | 2021-06-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013525476A (ja) | 2010-05-04 | 2013-06-20 | ファイザー・インク | Ａｌｋ阻害剤としての複素環式誘導体 |
| EP2643314B1 (en) * | 2010-11-25 | 2016-07-13 | ratiopharm GmbH | Novel salts and polymorphic forms of afatinib |
| US9422226B2 (en) | 2011-06-08 | 2016-08-23 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
| HUE034118T2 (en) | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3013835B1 (en) * | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
| EP3183256A4 (en) * | 2014-08-20 | 2018-05-30 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| ES2842302T3 (es) | 2015-07-31 | 2021-07-13 | Pfizer | Forma cristalina de base libre de lorlatinib |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
-
2018
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active Active
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en not_active Ceased
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019073347A1 (en) | 2019-04-18 |
| MX2020003373A (es) | 2020-10-12 |
| PT3694863T (pt) | 2023-08-23 |
| TWI775960B (zh) | 2022-09-01 |
| CA3077508C (en) | 2023-02-14 |
| US11299500B2 (en) | 2022-04-12 |
| KR20200051781A (ko) | 2020-05-13 |
| HUE062926T2 (hu) | 2023-12-28 |
| CA3077508A1 (en) | 2019-04-18 |
| EP3694863A1 (en) | 2020-08-19 |
| CY1126141T1 (el) | 2023-11-15 |
| EP3694863B1 (en) | 2023-06-21 |
| US20200308191A1 (en) | 2020-10-01 |
| ZA202001661B (en) | 2023-11-29 |
| AU2018349259A1 (en) | 2020-04-09 |
| BR112020005989A2 (pt) | 2020-09-29 |
| PL3694863T3 (pl) | 2023-09-25 |
| JP2020536893A (ja) | 2020-12-17 |
| TW201922753A (zh) | 2019-06-16 |
| RU2020113141A (ru) | 2021-11-12 |
| SG11202002445SA (en) | 2020-04-29 |
| SI3694863T1 (sl) | 2023-10-30 |
| JP7153069B2 (ja) | 2022-10-13 |
| CN111201235B (zh) | 2023-02-10 |
| ES2952985T3 (es) | 2023-11-07 |
| FI3694863T3 (fi) | 2023-08-18 |
| RU2022109286A (ru) | 2022-05-06 |
| CN111201235A (zh) | 2020-05-26 |
| AU2018349259B2 (en) | 2021-02-18 |
| RU2020113141A3 (enExample) | 2021-11-12 |
| KR102424621B1 (ko) | 2022-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3694863T3 (da) | Krystallinsk form af frit basehydrat af lorlatinib | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3978483T3 (da) | Krystallinsk toluensolvat af (s)-afoxolaner | |
| DK3328867T3 (da) | Krystallinsk form af fri base af lorlatinib | |
| DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
| DK3668851T3 (da) | Fremgangsmåde til fremstilling af thiocarbonater | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3565542T3 (da) | Polymorphic forms of rad1901-2hcl | |
| DK3457851T3 (da) | Derivater af sobetirom | |
| DK3220891T3 (da) | Sublingual formulering af riluzol | |
| DK3943070T3 (da) | Langtidsvirkende formuleringer af bedaquilin | |
| DK3474822T3 (da) | Formuleringer af brincidofovir | |
| IT201700028116A1 (it) | Gruppo di attuazione rotativo-lineare | |
| DK3113773T3 (da) | Krystallinske former af grapiprant | |
| IL269792B (en) | Crystalline forms of (s)-afoxolaner | |
| DK3678644T3 (da) | Formuleringer af copanlisib | |
| DK3529236T3 (da) | Krystalformer af eravacyclin | |
| DK3430004T3 (da) | Faststofformer af nilotinibsalte | |
| DK3173071T3 (da) | Formularing af maropitant | |
| DK3247687T3 (da) | Anvendelse af nivelleringsforbindelse | |
| DK3380453T3 (da) | Syntese af beta-mercaptoethanol | |
| DK3353147T3 (da) | Syntese af terphenylforbindelser | |
| DK3284267T3 (da) | Ophængning af en række højttalere | |
| LT3652187T (lt) | Patobulintas imetelstato gamybos būdas | |
| EP3612182A4 (en) | PATCH CONTAINING RUPATADINE |